Stapled peptide-based membrane fusion inhibitors of hepatitis C virus

被引：61

作者：

Cui, Hong-Kui ^{[1
]}

Qing, Jie ^{[1
]}

Guo, Ye ^{[1
]}

Wang, Yu-Jia ^{[1
]}

Cui, Li-Jia ^{[2
,3
]}

He, Tian-Hua ^{[2
,3
]}

Zhang, Linqi ^{[2
,3
]}

Liu, Lei ^{[1
]}

机构：

[1] Tsinghua Univ, Dept Chem, Tsinghua Peking Ctr Life Sci,Minist Educ, Key Lab Bioorgan Phosphorus Chem & Chem Biol, Beijing 100084, Peoples R China

[2] Tsinghua Univ, Sch Med, Comprehens AIDS Res Ctr, Beijing 100084, Peoples R China

[3] Tsinghua Univ, Sch Med, Res Ctr Publ Hlth, Beijing 100084, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2013年 / 21卷 / 12期

基金：

中国国家自然科学基金;

关键词：

Hepatitis C virus; Stapled peptide; Protein-protein interaction; CELL-CULTURE SYSTEMS; B TYPE-I; OLEFIN METATHESIS; ALPHA-HELICES; BH3; HELIX; CD81; ENTRY; INFECTION; PROTEINS; RECEPTOR;

D O I：

10.1016/j.bmc.2013.02.011

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The strategy of peptide stapling was used to develop new molecules to inhibit the hepatitis C virus infection via disrupting the binding of HCV envelope glycoprotein E2 with human cell surface protein CD81. The peptide sequence was designed based on the large extra-cellular loop of CD81 with known importance in the HCV E2 binding interaction. Our results showed that the stapled peptides exhibited significantly higher alpha-helicity and proteolytic stability as compared to their linear peptide counterpart. The optimal compound was found to have an EC50 value of ca. 17-39 mu M against different HCV subtypes and represented a new HCV membrane fusion inhibitor. (C) 2013 Elsevier Ltd. All rights reserved.

引用

下载

页码：3547 / 3554

页数：8

共 50 条

[41] Rational design of tropoelastin peptide-based inhibitors of metalloproteinases
Jensen, SA
Andersen, P
Vrhovski, B
Weiss, AS
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 409 (02) : 335 - 340
[42] The development of peptide-based inhibitors of Stat3α
Ren, Zhiyong
Coleman, David R.
Cabell, Larry A.
McMurray, John S.
PEPTIDE REVOLUTION: GENOMICS, PROTEOMICS & THERAPEUTICS, 2004, : 550 - 552
[43] Peptide-Based Proteasome Inhibitors in Anticancer Drug Design
Micale, Nicola
Scarbaci, Kety
Troiano, Valeria
Ettari, Roberta
Grasso, Silvana
Zappala, Maria
MEDICINAL RESEARCH REVIEWS, 2014, 34 (05) : 1001 - 1069
[44] Peptide-based inhibitors of amyloid beta aggregation and toxicity
Rodriguez, Maria Zabala
Teter, Ken
Tatulian, Suren
BIOPHYSICAL JOURNAL, 2023, 122 (03) : 352A - 353A
[45] Design and study of peptide-based inhibitors of amylin cytotoxicity
Muthusamy, Karen
Arvidsson, Per I.
Govender, Patrick
Kruger, Hendrik G.
Maguire, Glenn E. M.
Govender, Thavendran
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (04) : 1360 - 1362
[46] The development of peptide-based inhibitors of Stat3α
Ren, Z
Coleman, DR
Cabell, LA
McMurray, JS
BIOPOLYMERS, 2003, 71 (03) : 392 - 392
[47] IN SILICO PEPTIDE BASED VACCINE AGAINST HEPATITIS C VIRUS
Kaushik, Vikas
Singh, Joginder
Sharma, Nidhi
2016 INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND SYSTEMS BIOLOGY (BSB), 2016,
[48] Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors
Su, Shan
Zhu, Yun
Ye, Sheng
Qi, Qianqian
Xia, Shuai
Ma, Zhenxuan
Yu, Fei
Wang, Qian
Zhang, Rongguang
Jiang, Shibo
Lu, Lu
JOURNAL OF VIROLOGY, 2017, 91 (01)
[49] Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction
Fumakia, Miral
Yang, Sidi
Gu, Jijin
Ho, Emmanuel A.
REVIEWS IN MEDICAL VIROLOGY, 2016, 26 (01) : 4 - 20
[50] Systematic Evaluation of Fluorination as Modification for Peptide-Based Fusion Inhibitors against HIV-1 Infection
Huhmann, Susanne
Nyakatura, Elisabeth K.
Rohrhofer, Anette
Moschner, Johann
Schmidt, Barbara
Eichler, Jutta
Roth, Christian
Koksch, Beate
CHEMBIOCHEM, 2021, 22 (24) : 3443 - 3451

← 1 2 3 4 5 →